IART Integra LifeSciences Holdings

Seven brokerages have issued a "Reduce" consensus rating for Integra LifeSciences Holdings Corporation (NASDAQ:IART), with an average 1-year price target of $15.00. This rating follows mixed quarterly results, where the company beat EPS expectations but missed revenue estimates and provided lower-than-analyst-expected Q4 and FY2025 guidance. Insider activity shows a director increasing their stake, while institutional investors hold a significant portion of the stock.

Integra LifeSciences Holdings Corporation announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025, at 10:30 a.m. ET. A live webcast of their presentation will be available on the company's investor relations website. The company aims to restore patients' lives through innovating treatment pathways and advancing surgical, neurologic, and regenerative care.

Integra LifeSciences (Nasdaq: IART) announced that CEO Mojdeh Poul and CFO Lea Knight will present at the Citi 2025 Global Healthcare Conference on December 3, 2025, at 10:30 a.m. ET. A live webcast of their presentation will be available on the company's investor relations website under "Events & Presentations." The company, a global medical technology leader, aims to share its vision for restoring patients' lives through innovation in surgical, neurologic, and regenerative care.

Integra LifeSciences has applauded a recent CMS ruling for its 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which includes reimbursement for their dermal regenerative templates and other skin substitute products. This ruling ensures a uniform reimbursement rate across care settings, enhancing patient access to Integra's wound reconstruction products. The company believes this will reward innovation, quality, and improved patient outcomes, leading to expanded access to their diverse portfolio of cost-effective wound reconstruction solutions.

Integra LifeSciences Holdings Corporation commends CMS for its new Calendar Year 2026 Medicare Physician Fee Schedule and Outpatient Prospective Payment System rules, which include all of Integra's skin substitute products. These policy advancements will allow Integra to expand access to its diverse portfolio of wound reconstruction solutions by establishing a uniform reimbursement rate across care settings. The company believes this will reward innovation, quality, and patient outcomes, aligning with Integra's leadership in these areas.

Integra LifeSciences commends the Centers for Medicare & Medicaid Services (CMS) for its Calendar Year 2026 rules that modernize payment structures to support broader access for Medicare beneficiaries to various skin substitutes. The new policies include all Integra dermal regenerative templates, decellularized dermal scaffolds, and amniotic tissue membranes, ensuring a uniform reimbursement rate across care settings. This development is expected to expand access to Integra's diverse portfolio of wound reconstruction solutions, which are backed by strong clinical evidence and innovative technology platforms.